辰欣藥業(603367.SH)獲炎熱清片生產技術轉讓批准文號
格隆匯10月9日丨辰欣藥業(603367.SH)公佈,近日,公司收到國家藥品監督管理局核准簽發的《藥品補充申請批件》。同意湖北華龍生物製藥有限公司將炎熱清片藥品生產技術轉讓至辰欣藥業股份有限公司。
炎熱清片,為清熱解毒類中成藥,用於呼吸道炎、支氣管炎、肺炎、急性扁桃體炎。也可用於泌尿系感染、膽道感染。目前,國內共有13個炎熱清片生產廠家。隨着最近幾年針對抗生素濫用的“限抗令”全面鋪開,中成藥類抗菌消炎藥成為醫生和患者的治療選擇。2013年至2016年,我國清熱解毒類口服中成藥市場銷售額從165.14億元增長到206.44億元,複合增長率為7.72%。預計到2022年我國清熱解毒類口服中成藥市場銷售額在317.91億元左右,2017-2022年複合增長率在7.5%左右。摘自智研諮詢發佈的《2017-2023年中國清熱解毒口服液市場專項調研及投資方向研究報告》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.